• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

    3/27/25 8:05:00 AM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RIGL alert in real time by email

    SOUTH SAN FRANCISCO, Calif., March 27, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc. (collectively "Annora") resolving patent litigation related to Rigel's product TAVALISSE® (fostamatinib disodium hexahydrate). The litigation resulted from submission by Annora of an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of TAVALISSE in the United States. Under the terms of the settlement agreement, Annora will have a license to sell its generic product in Q2 2032 or earlier under certain circumstances. In accordance with the agreement, the parties terminated all ongoing litigation between Rigel and Annora regarding TAVALISSE patents pending in New Jersey.

    "The resolution of this patent litigation underscores the strength of Rigel's intellectual property protecting TAVALISSE, an innovative treatment for people with immune thrombocytopenia," said Raul Rodriguez, Rigel's president and CEO. "We remain committed to advancing our portfolio of novel therapies with the potential to improve the lives of patients with hematological disorders and cancer, and to continue to develop and enhance our intellectual property portfolio."

    About ITP

    In patients with immune thrombocytopenia (ITP), the immune system attacks and destroys the body's own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding. Patients suffering with chronic ITP may live with an increased risk of severe bleeding events that can result in serious medical complications or even death. Current therapies for ITP include steroids, blood platelet production boosters (TPO-RAs), and splenectomy. However, not all patients respond to existing therapies. As a result, there remains a significant medical need for additional treatment options for patients with ITP.

    About TAVALISSE®

    TAVALISSE (fostamatinib disodium hexahydrate) tablets is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

    Please click here for Important Safety Information and Full Prescribing Information for TAVALISSE.

    To report side effects of prescription drugs to the FDA, www.fda.gov/medwatch or call 1-800-FDA-1088 (800-332-1088).

    TAVALISSE is a registered trademark of Rigel Pharmaceuticals, Inc.

    About Rigel

    Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

    Forward Looking Statements

    This press release contains forward-looking statements relating to, among other things, expected generic product market entry, the strength of our intellectual property portfolio and our ability to develop and enhance it, TAVALISSE as a treatment for immune thrombocytopenia, and expectations to grow and advance our commercial portfolio. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements can be identified by words such as "anticipates", "plan", "potential", "may", "look to", "expects", "will", "initial", "promising", and similar expressions in reference to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Rigel's current beliefs, expectations, and assumptions and hence they inherently involve significant risks, uncertainties and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the commercialization and marketing of fostamatinib, olutasidenib and pralsetinib; risks that the FDA, European Medicines Agency, PMDA or other regulatory authorities may make adverse decisions regarding fostamatinib, pralsetinib or olutasidenib; risks that clinical trials may not be predictive of real-world results or of results in subsequent clinical trials; risks that fostamatinib, pralsetinib or olutasidenib may have unintended side effects, adverse reactions or incidents of misuses; the availability of resources to develop Rigel's product candidates; market competition; as well as other risks detailed from time to time in Rigel's reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent filings. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Rigel does not undertake any obligation to update forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.

    Contact for Investors & Media:

    Investors:

    Rigel Pharmaceuticals, Inc.

    650.624.1232

    [email protected] 

    Media:

    David Rosen

    Argot Partners

    646.461.6387

    [email protected]

    Rigel Pharmaceuticals Logo (PRNewsfoto/Rigel Pharmaceuticals, Inc.)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-announces-settlement-agreement-resolving-tavalisse-fostamatinib-disodium-hexahydrate-patent-litigation-302412838.html

    SOURCE Rigel Pharmaceuticals, Inc.

    Get the next $RIGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RIGL

    DatePrice TargetRatingAnalyst
    4/3/2023$2.00Neutral
    Piper Sandler
    6/9/2022Buy → Neutral
    Citigroup
    6/8/2022$7.00 → $1.00Overweight → Neutral
    Piper Sandler
    6/8/2022$6.00 → $1.00Overweight → Neutral
    Cantor Fitzgerald
    3/23/2022$4.00Neutral
    B. Riley Securities
    More analyst ratings

    $RIGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

      First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million Generated $11.4 million of net income in the first quarter of 2025R289 granted Orphan Drug designation for the treatment of MDS and Fast Track designation for the treatment of previously-treated transfusion dependent lower-risk MDS by the FDA2025 Outlook: Total revenue of approximately $200 to $210 millionConference call and webcast scheduled today at 4:30 p.m. Eastern TimeSOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on

      5/6/25 4:01:00 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

      SOUTH SAN FRANCISCO, Calif., April 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will report its first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business. Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's webs

      4/29/25 8:05:00 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

      SOUTH SAN FRANCISCO, Calif., April 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (NASDAQ:RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 23,350 stock options and restricted stock units to seven non-executive employees vesting over four years with a one-year cliff.   About RigelRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a biotechnology company dedicated to discovering, developing a

      4/4/25 8:05:00 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Rigel Pharmaceuticals Inc.

      SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)

      11/14/24 5:18:08 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rigel Pharmaceuticals Inc.

      SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)

      11/14/24 3:33:13 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Rigel Pharmaceuticals Inc.

      SC 13G - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)

      11/8/24 9:33:38 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler resumed coverage on Rigel Pharma with a new price target

      Piper Sandler resumed coverage of Rigel Pharma with a rating of Neutral and set a new price target of $2.00

      4/3/23 9:11:21 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Pharma downgraded by Citigroup

      Citigroup downgraded Rigel Pharma from Buy to Neutral

      6/9/22 7:22:28 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Pharma downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Rigel Pharma from Overweight to Neutral and set a new price target of $1.00 from $7.00 previously

      6/8/22 1:49:43 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by EVP & Chief Financial Officer Schorno Dean L

      4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)

      3/19/25 8:56:36 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by EVP, Chief Commercial Officer Santos David A

      4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)

      3/19/25 8:56:27 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by EVP, Chief Medical Officer Rojkjaer Lisa

      4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)

      3/19/25 8:56:18 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    Financials

    Live finance-specific insights

    See more
    • Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

      First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million Generated $11.4 million of net income in the first quarter of 2025R289 granted Orphan Drug designation for the treatment of MDS and Fast Track designation for the treatment of previously-treated transfusion dependent lower-risk MDS by the FDA2025 Outlook: Total revenue of approximately $200 to $210 millionConference call and webcast scheduled today at 4:30 p.m. Eastern TimeSOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on

      5/6/25 4:01:00 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

      SOUTH SAN FRANCISCO, Calif., April 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will report its first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business. Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's webs

      4/29/25 8:05:00 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of $8.1 million 2024 total revenue of approximately $179.3 million, which includes TAVALISSE® net product sales of $104.8 million, REZLIDHIA® net product sales of $23.0 million and GAVRETO® net product sales of $17.1 millionR289 granted Fast Track designation for the treatment of previously-treated transfusion dependent lower-risk MDS and Orphan Drug designation for the treatment of MDS by the FDA2025 Outlook: Total revenue of approximately $200 to $210 millionConference call and webcast sch

      3/4/25 4:01:00 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    SEC Filings

    See more
    • Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)

      5/6/25 4:23:43 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Rigel Pharmaceuticals Inc.

      10-Q - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)

      5/6/25 4:05:42 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Rigel Pharmaceuticals Inc.

      SCHEDULE 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)

      4/17/25 9:35:38 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    Leadership Updates

    Live Leadership Updates

    See more
    • Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors

      SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a medical oncologist and brings more than 25 years of experience developing cellular immunotherapies to treat cancer, including deep expertise in clinical drug development and translational research, and portfolio strategy.   "We are pleased to have Mark join our Board," said Raul Rodriguez, Rigel's president and CEO. "His experience in clinical development, translational research and portfolio strategy will be a valuable addition to Rigel as we advance our hematology and oncology developm

      3/10/25 8:05:00 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer. Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on hematology and oncology. She is a board-certified hematologist with an international clinical practice background. "It is a pleasure to welcome Lisa to the team. She brings to Rigel a strong combination of industry leadership experience paired with drug development and regulatory affairs expertise. Her robust hematology and oncology knowledge comp

      3/12/24 8:05:00 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

      STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company's financial operations. "Ryan's deep financial leadership experience will be instrumental to the execution of Cara's long-term growth strategy as we continue to maximize the KORSUVA™ (difelikefalin) injection launch and advance our oral difelikefalin pipeline to establish our position

      9/12/22 7:00:00 AM ET
      $CARA
      $IOVA
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)